| Product Name | Nudol/2,7-dihydroxy-3,4-dimethoxyphenanthrene |
|---|---|
| CAS | 86630-46-8 |
| Formula | C16H14O4 |
| MW | 270.28 |
| Appearance | |
| Melting point | 185 °C |
| Boiling point | 512.4±45.0 °C | Condition: Press: 760 Torr |
| PKa | 9.38±0.30 | Condition: Most Acidic Temp: 25 °C |
| Product Name | Nudol/2,7-dihydroxy-3,4-dimethoxyphenanthrene |
|---|---|
| CAS | 86630-46-8 |
| Formula | C16H14O4 |
| MW | 270.28 |
| Appearance | |
| Melting point | 185 °C |
| Boiling point | 512.4±45.0 °C | Condition: Press: 760 Torr |
| PKa | 9.38±0.30 | Condition: Most Acidic Temp: 25 °C |
WKQ-0001975
中文名稱：2,7-二羥基-3,4-二甲氧基菲
英文名稱：Nudol/2,7-dihydroxy-3,4-dimethoxyphenanthrene
英文別名：3,4-Dimethoxy-2,7-phenanthrenediol;Nudol;
分子式：C16H14O4
分子量：270.28
CAS號：86630-46-8
純度：HPLC≥98%
熔點：185 °C
沸點：512.4±45.0 °C | Condition: Press: 760 Torr
密度：1.334±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：9.38±0.30 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應客戶需求包裝
供應單位：四川省維克奇生物科技有限公司
供應電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標準品和天然植物有效單體，主打中藥對照品/標準品/天然植物有效單體，化學合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關注！ 新批次有現(xiàn)貨，歡迎咨詢。
| Simultaneous Quantification of 11 Phenolic Compounds and Consistency Evaluation in Four Dendrobium Species Used as Ingredients of the Traditional Chinese Medicine Shihu | ||
| Source:SCI：Frontiers in Nutrition | Author:An-Ling Zhu | Notes：影響因子：6.576 |
| Reference description | ||
The double-distilled water was prepared in the laboratory by using a Milli-Q system (Millipore, Bedford, MA, USA). Schaftoside (1), isoschaftoside (2), 2,4,7-trihydroxy-9,10-dihydrophenanthrene (3), dihydroresveratrol (4), coelonin (5), nudol (6), gigantol (7), 4-methoxy-2,5- phenanthrenediol (8), 3-hydroxy-3,4,5-trimethoxybibenzy (9), erianin (10), and tristin (11) were purchased from Sichuan Weikeqi Biological Technology Co., Ltd. (Sichuan province, Chengdu, China). The purity of all the reference standards was above 98%. The structures of these standards are shown in Figure 1. | ||
